Similar Items: Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development
- The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
- Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study
- Technology advancements in antibody purification [Corrigendum]
- Trispecific antibodies: is more always better? Advances and boundaries
- Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives
- The production of murine monoclonal antibodies using in vitro immunization